Clinical trial
Rituximab in New Onset Type 1 Diabetes
NCT00279305 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00279305 |
|---|---|
| Title | Rituximab in New Onset Type 1 Diabetes |
| Official title | Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects |
| Acronym | TN05 |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) American Diabetes Association Juvenile… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Anti-CD20 (rituximab), Placebo Comparator |
| Enrollment | 87 |
| Start date | Aug 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jan 19, 2006 |
| Last update posted | May 6, 2020 |
| Countries | Australia, Canada, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: